Recombinant Human Antibody (3bnc117) is capable of binding to HIV-1 gp120, expressed in HEK 293 cells. Expressed as the combination of a heavy chain (HC) containing VH from anti-HIV-1 gp120 mAb and CH1-3 region of human IgG1 and a light chain (LC) encoding VL from anti-HIV-1 gp120 mAb and CL of human light chain. Exists as a disulfide linked dimer of the HC and LC hetero-dimer under non-reducing condition.
Figure 4 (D–F) ELISA assays to determine dual specificity of the 3BNC117/10-1074 biNAb.
(D) Competition ELISA with increasing concentrations of each of the parental bNAbs or a mixture (1:1) of the two bNAbs to determine dual specificity of the biNAb. (E) The 3BNC117/10-1074 biNAb and the 3BNC117 and 10-1074 bNAbs were immobilized to gp140-coated microtiter plates and detected using Fc domain- or light-chain (κ or λ) subclass-specific secondary IgG. The biNAb was detected with both the anti-kappa and anti-lambda secondary antibodies, whereas 3BNC117 and 10-1074 were detected only with anti-kappa or anti-lambda, respectively.
Bournazos, S., Gazumyan, A., Seaman, M. S., Nussenzweig, M. C., & Ravetch, J. V. (2016). Bispecific anti-HIV-1 antibodies with enhanced breadth and potency. Cell, 165(7), 1609-1620.
Figure 5 (G) In vitro neutralization breadth and potency plot of 3BNC117/10-1074 IgG1 biNAb against an extended (120 strain) multiclade virus panel.
Neutralization activity of their respective parental IgG1 bNAbs was included for comparison. The 3BNC117/10-1074 IgG1 biNAb exhibited marked reduction in neutralization potency compared to the activity of a mix of their parental mAbs (determined based on the activity of the most potent parental mAb for a given virus strain)
Bournazos, S., Gazumyan, A., Seaman, M. S., Nussenzweig, M. C., & Ravetch, J. V. (2016). Bispecific anti-HIV-1 antibodies with enhanced breadth and potency. Cell, 165(7), 1609-1620.
Figure 6 In vitro neutralization breadth and potency plots of different anti-Env bNAb expressed as IgG1 or IgG3C- hinge variants. In vitro neutralization was assessed by TZMbl assay against an extended multiclade virus panel.
Bournazos, S., Gazumyan, A., Seaman, M. S., Nussenzweig, M. C., & Ravetch, J. V. (2016). Bispecific anti-HIV-1 antibodies with enhanced breadth and potency. Cell, 165(7), 1609-1620.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
NABG-082 | Recombinant Anti-HIV-1 gp120 VHH Single Domain Antibody | ELISA, IHC, FC, FuncS | Llama VHH |
MRO-028LC-VHH | Anti-HIV-1 gp120 Recombinant Antibody (MRO-028LC-VHH) | ELISA | Single domain antibody |
MRO-029LC-VHH | Anti-HIV-1 gp120 Recombinant Antibody (MRO-029LC-VHH) | ELISA | Single domain antibody |
MRO-030LC-VHH | Anti-HIV-1 gp120 Recombinant Antibody (MRO-030LC-VHH) | ELISA | Single domain antibody |
MRO-031LC-VHH | Anti-HIV-1 gp120 Recombinant Antibody (MRO-031LC-VHH) | ELISA | Single domain antibody |
There are currently no Customer reviews or questions for PABL-163. Click the button above to contact us or submit your feedback about this product.
To accurately reference this product in your publication, please use the following citation information:
(Creative Biolabs Cat# PABL-163, RRID: AB_3111632)
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.